Here, we present evidence that ING4 inhibits NF-κB in breast cancer cells and propose that down-regulation of ING4 is one of the molecular events that leads to NF-κB activation, promoting tumor progression and resulting in reduced patient survival in breast cancer. This evidence concerns the gene NFKB1 and breast cancer.